目的：研究乳腺癌新辅助化疗疗效与生物学标志物P53、Ki-67表达的相关性。寻求新辅助化疗有效的生物学标志物预测因子。方法我院乳腺外科2008.1～2012.12收治的49例接受新辅助化疗的乳腺癌患者作为研究对象。应用免疫组化方法检测新辅助化疗前 P53、Ki-67的表达情况，化疗2～6周期后评价临床疗效，统计分析生物学标志物和化疗疗效的相关性。结果49例新辅助化疗的病例中，P53、Ki-67阳性率分别是52.2%、39.1%。新辅助化疗总有效率79.6%。临床完全缓解率34.7%，临床部分缓解率44.9%，疾病稳定18.4%，疾病进展2.0%，病理完全缓解率10.2%。结论 P53阴性和Ki-67阳性的乳腺癌对新辅助化疗更为敏感，P53、Ki-67可作为新辅助化疗有效率的预测因子。%Objective To study the correlation of biological markers P53、Ki-67expression in breast cancer with the ef ect of neoadjuvant chemotherapy (NAC).To search predictive factors of NAC. Methods From Jun 2008 to Dec 2012,49 breast cancer patients in our hospital with NAC were enrol ed in the sthdy.The expressions of P53、Ki-67 were detected by immunohistochemical method before NAC. Reponse rate was evaluated after 2~6 cycles of NAC.The correlation between expressions of biomarkers and the ef ect of NAC were analyzed. Results Among the 49 cases of NAC,the positive expression rate of P53、Ki-67 was 52.2%、39.1%,respectively. The clinical reponse rate (RR)was 79.6%,with clinical completed response (cCR)34.7%,clinical partial reponse (cPR)44.9%,stable disease (SD)18.4%,progressive disease (PD)2.0%,pathologic complete reponse(pCR)10.2%. Conclusion:In the breast cancer patients,P53 negative and Ki-67 positive tunors are more sensitive to NAC.P53、Ki-67 can be considered as predictive markers of the ef ect of NAC.
展开▼
